Crossmark

Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”

Published Online: 2023-10-25

Published Print: 2023-12

Authors

Behdarvand Dehkordi, Fereshteh

Chehelgerdi, Mohammad
License Information

Text and Data Mining valid from 2023-10-25

Version of Record valid from 2023-10-25
More Information

Article History

Received: 2 September 2023

Accepted: 4 October 2023

First Online: 25 October 2023

Declarations

:

: No application.

: Not applicable.

: The authors declare no competing interests.

Document is current